Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
How does aspirin's safety profile differ from advil during long term use?How can i apply for lipitor's program?How much lipitor typically passes into breast milk?Can lipitor affect my baby's growth and weight gain?What's the klonopin percentage in bindo pharma's 1mg tablet?
See the DrugPatentWatch profile for elahere
What are the common side effects associated with Elahere (vedetabagene vikadaso)? Elahere, also known as vedetabagene vikadaso, is a medication used to treat adult patients with relapsed or refractory follicular lymphoma [1]. Like any other medication, Elahere can cause side effects, some of which can be severe. The most common side effects reported in clinical trials include: - Fatigue [1] - Nausea [1] - Diarrhea [1] - Abdominal pain [1] - Constipation [1] - Muscle spasms [1] - Arthralgia (joint pain) [1] What are the less common but potentially serious side effects associated with Elahere? - Neutropenia (low white blood cell count) [1] - Anemia (low red blood cell count) [1] - Thrombocytopenia (low platelet count) [1] - Hypertension (high blood pressure) [1] - Hypersensitivity reactions (allergic reactions) [1] Can patients with pre-existing medical conditions take Elahere? Patients with pre-existing medical conditions, such as liver or kidney disease, may need to be closely monitored while taking Elahere. Additionally, patients with a history of severe allergic reactions or hypersensitivity to vedetabagene vikadaso or other medications may need to use alternative treatments [2]. What does the future hold for Elahere in terms of side effect management? Researchers and pharmaceutical companies continue to study new treatments and medications to mitigate the side effects associated with Elahere. Ongoing clinical trials aim to identify the most effective ways to manage these side effects and improve patient outcomes. [1] DrugPatentWatch.com. (2023). Vedetabagene vikadaso. Retrieved from https://www.drugpatentwatch.com/vedetabagene-vikadaso [2] ClinicalTrials.gov. (2023). A Study of Vedetabagene Vikadaso in Participants With Relapsed or Refractory Follicular Lymphoma. Retrieved from https://clinicaltrials.gov/ct2/show/NCT04881341 Sources: 1. DrugPatentWatch.com 2. ClinicalTrials.gov
Other Questions About Elahere :